Why We Invested in Statera: The Next Generation of Shoulder Prostheses
Providing surgeons with the data and tools they need for shoulder replacement
By 2025, 170 000 patients in North America will undergo shoulder replacement surgery annually, a procedure in which the damaged shoulder parts are replaced with a prosthesis. Unfortunately, 15% of these patients experience complications within a year of the surgery.
This high complication rate can be explained by the lack of data and tools at the disposal of surgeons during shoulder replacement surgery. The success of this procedure largely depends on the surgeon’s ability to attain the right tension in the patient’s shoulder muscles. This soft tissue balance is unique to each patient, yet surgeons do not have access to reliable, objective tension data. Currently, surgeons rely on their experience and techniques like bicep tendon palpation to assess whether they have obtained the right soft tissue balance.
Frédérik and Samuel founded Statera Medical to tackle these challenges by developing the next generation of orthopaedic devices for patients requiring total shoulder joint replacement.
The Solution: TeraLife
TeraLife is an instrumented implant and software solution which offers surgeons pre-operative, intra-operative, and post-operative insights. The system’s key features lie in its data collection and transmission abilities, and in its patented mechanical adjustment system.
- TeraLife has a proprietary force measurement system and accompanying software, which provide surgeons with data on the tension in the shoulder muscles, on the condition of the implant, and on the likelihood of the surgery to be a success. This data will allow surgeons to better prevent the main causes of revision surgery: fractures and joint instability.
- TeraLife also has a patented patient-specific mechanical adjustment system, which significantly increases the range of motion achieved by traditional rigid shoulder prostheses. If post-operative adjustments need to be made, TeraLife’s mechanical adjustment system allows the surgeon to make them in the most minimally invasive manner possible, a true innovation in the space.
The TeraLife implant’s advanced technology allows the surgeon to better replicate the patient’s original joint, leading to far better patient outcomes and drastically lower costs to the medical system. It truly represents the future of joint replacement.
So What’s Next?
We strongly believe in the founders, Samuel and Frédérik, who saw a clear problem in the shoulder orthopaedics space, and created a solution to tackle it. The company’s Chief Medical Officer, Moreno Morelli, has over 20 years of experience in orthopaedics.
With our investment, Statera is looking to continue developing the technology through in-vitro tests and to grow their headcount. They are truly an exceptional team, so if you are looking to contribute to their mission of improving surgical outcomes, don’t hesitate to reach out!
We are truly thrilled to partner with a company that seeks to meaningfully improve the health of shoulder replacement patients.